ZLNA ZELLUNA ASA

Zelluna ASA – Extraordinary General Meeting held on November 25, 2025

Zelluna ASA – Extraordinary General Meeting held on November 25, 2025

Oslo, November 25, 2025: Zelluna ASA held its extraordinary general meeting today November 25, 2025. All the matters on the agenda were approved. 

The minutes from the meeting are enclosed and available at the company’s website.

For further information, please see or contact:

Anders Tuv, Chairman of the Board of Directors of Zelluna ASA

Email: 

Phone:

Namir Hassan, CEO, Zelluna ASA

Email: 

Phone:

Hans Vassgård Eid, CFO, Zelluna ASA

Email: 

Phone:  



 

Attachments



EN
25/11/2025

Underlying

ZLNAZELLUNA ASA

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ZELLUNA ASA

 PRESS RELEASE
Free
ZLNA ZELLUNA ASA

Zelluna Reaches Major Milestone and Submits Clinical Trial Application...

Zelluna Reaches Major Milestone and Submits Clinical Trial Application in the UK for First-in-Human Study of ZI-MA4-1 (ZIMA-101), the World’s First MAGE-A4-Targeting TCR-NK Cell Therapy for Solid Tumours On track for initial clinical data in mid-2026Marks a pivotal step toward scalable, accessible, off-the-shelf cell therapies for solid tumours Oslo, Norway, 17 December 2025 – Zelluna (OSE: ZLNA), a company pioneering allogeneic off-the-shelf cell therapies for cancer, today announced the submission of its Clinical Trial Application (CTA) to the UK Medicines and Healthcare products Regulat...

December 17, 2025 1 EN
 PRESS RELEASE
Free
ZLNA ZELLUNA ASA

Zelluna har nådd en viktig milepæl og innleverer søknad om klinisk stu...

Zelluna har nådd en viktig milepæl og innleverer søknad om klinisk studie i Storbritannia for første studie på mennesker av ZI-MA4-1 (ZIMA-101), verdens første MAGE-A4-rettede TCR-NK celleterapi for solide kreftformer. Forventer første kliniske data fra midten av 2026Markerer et viktig skritt mot skalerbare, tilgjengelige "off-the-shelf" celleterapier for solide kreftformer Oslo, Norge, 17. desember 2025 – Zelluna (OSE: ZLNA), et bioteknologiselskap som utvikler allogene "off-the-shelf" celleterapier mot kreft, kunngjorde i dag at selskapet har innlevert søknad om oppstart av klinisk studi...

December 17, 2025 1 EN
 PRESS RELEASE
Free
ZLNA ZELLUNA ASA

Zelluna Publishes Compelling Preclinical Data for ZI-MA4-1, the World'...

Zelluna Publishes Compelling Preclinical Data for ZI-MA4-1, the World's First MAGE-A4-Targeting TCR-NK Therapy for Solid Tumours Strong preclinical data support planned clinical trial initiation in 2026 Oslo, Norway, 16 December 2025– Zelluna (OSE: ZLNA), a company developing off-the-shelf cell therapies for cancer, today announced the publication of preclinical data for its lead candidate, ZI-MA4-1, in the peer-reviewed journal Immunotherapy Advances*. The data support the company's plan to start clinical trials in 2026. The paper describes ZI-MA4-1, a novel cell therapy that combines tw...

December 16, 2025 1 EN
 PRESS RELEASE
Free
ZLNA ZELLUNA ASA

Zelluna Completes First GMP Batch of ZI-MA4-1, a Novel TCR-NK Cell The...

Zelluna Completes First GMP Batch of ZI-MA4-1, a Novel TCR-NK Cell Therapy, to Treat Patients in Upcoming First-in-Human Trial On track to file a Clinical Trial Application (CTA) by year end 2025, with initial clinical data expected mid-2026Important step in developing scalable and accessible ‘off-the-shelf’ cell therapy for patients with solid tumours Oslo, Norway, 12 December, 2025 – Zelluna (OSE: ZLNA), a company pioneering allogeneic “off-the-shelf” T Cell Receptor-based Natural Killer (TCR-NK) cell therapies for the treatment of cancer, today announced the successful manufacture and Q...

December 12, 2025 1 EN
 PRESS RELEASE
Free
ZLNA ZELLUNA ASA

Zelluna ASA: Cancellation of subsequent repair offering

Zelluna ASA: Cancellation of subsequent repair offering NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN OR ANY JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. Oslo, 9 December, 2025: Reference is made to the stock exchange announcement published by Zelluna ASA ("Zelluna" or the "Company") on 3 November 2025 regarding the private placement (the "Private Placement"), and the intention to carry out a subsequent repair offering (the "Subsequent Offering"), depending, inter alia, on...

December 9, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch